Future studies in HER2+ breast cancers would determine conditional loss of MYH9 in HER2+ breast cancer xenografts in vivo and additionally examine the efficacy of inhibitors of ROCK, upstream of NMIIA, in combination with HER2 inhibition. This evidence concerns the gene ERBB2 and breast cancer.